Inicio>>Signaling Pathways>> DNA Damage/DNA Repair>> Casein Kinase>>Epiblastin A

Epiblastin A

Catalog No.GC43618

La epiblastina A es un inhibidor competitivo de ATP de la caseÍna quinasa 1 (CK1) con IC50 de 8,9, 0,5 y 4,7 μM para CK1α, CK1δ y CK1 ɛ, respectivamente. La epiblastina A induce la reprogramaciÓn de las células madre del epiblasto en células madre embrionarias mediante la inhibiciÓn de CK1.

Products are for research use only. Not for human use. We do not sell to patients.

Epiblastin A Chemical Structure

Cas No.: 16470-02-3

Tamaño Precio Disponibilidad Cantidad
1mg
33,00 $
Disponible
5mg
105,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Epiblastin A is an ATP-competitive inhibitor of the casein kinase 1 (CK1) isoforms α, δ, and ε (IC50s = 8.9, 0.5, and 4.7 μM, respectively). [1] It is selective for CK1α, CK1δ, and CK1ε at concentrations below 10 μM, however, it also inhibits BRSK1, EEF2K, EGFR, MNK-2, and RIPK2 (IC50s = 24-45 μM). Epiblastan A reduces immunoprecipitation of CK1α, CK1δ, and CK1ε from HCT116 cell lysates in a concentration-dependent manner. It induces reprogramming of mouse epiblast stem cells (mEpiSCs) into embryonic stem cells (ESCs) 8-fold more efficiently than triamterene .

Reference:
[1]. Ursu, A., Illich, D.J., Takemoto, Y., et al. Epiblastin A induces reprogramming of epiblast stem cells into embryonic stem cells by inhibition of Casein Kinase 1. Cell Chem. Biol. 23(4), 494-507 (2016).

Reseñas

Review for Epiblastin A

Average Rating: 5 ★★★★★ (Based on Reviews and 9 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Epiblastin A

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.